Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2022 17:01 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics宣布ADG20（adintrevimab）是首个在新冠病毒暴露前和暴露后预防和治疗中达到主要终点且具有统计学意义的单克隆抗体，并计划寻求美国紧急使用授权

与安慰剂相比，症状性新冠肺炎风险在暴露前预防中降低了71%，在接触后预防中则降低了75% 在主要疗效分析人群中，与安慰剂相比，轻度至中度新冠肺炎患者的住院或死亡风险降低了66%，在症状出现三天内接受治疗的人群中，住院或死亡风险与安慰剂相比降低了77% 报告了2021年全年和第四季度的财务业绩；预计5.91亿美元的现金和投资将足以为2024年下半年的运营提供资金 ...
March 31, 2022 17:01 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics anuncia que ADG20 (adintrevimab) es el primer anticuerpo monoclonal que cumple con los principales criterios de valoración con importancia estadística en la profilaxis pre-exposición (PrEP) y profilaxis post-exposición (PEP).y tratamiento de COVID-19 y planea solicitar autorización de uso de emergencia en Estados Unidos

El riesgo de COVID-19 sintomático fue reducido en un 71% en comparación con placebo en la profilaxis pre-exposición y 75% en comparación con placebo en la profilaxis post-exposición El riesgo de...
March 31, 2022 17:01 ET | Source: Adagio Therapeutics, Inc.

アダジオ・セラピューティクス（Adagio Therapeutics）、ADG20（Adintrevimab）が新型コロナウイルスの暴露前後の予防と治療において統計的に有意な主要エンドポイントを満たす最初のモノクローナル抗体であり、米国の緊急使用許可を求める予定であると発表

症候性新型コロナウイルスのリスクは、プラセボと比較して、暴露前予防では71％減少、暴露後予防では75％減少軽度から中等度の新型コロナウイルス暴露者の入院または死亡のリスクは、一次有効性分析集団のプラセボと比較して66％減少、症状発現から3日以内に治療を受けた参加者のプラセボと比較して77％減少 2021年度通期および第4四半期の決算を報告。...
March 31, 2022 17:01 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics gibt bekannt, dass ADG20 (Adintrevimab) der erste monoklonale Antikörper ist, der die primären Endpunkte der Prophylaxe vor und nach Exposition sowie der Behandlung von COVID-19 mit statistischer Signifikanz erreicht hat, und plant die Beantragung der Notfallzulassung in den USA

Das Risiko einer symptomatischen COVID-19-Erkrankung wurde bei der Prophylaxe vor Exposition um 71 % und bei der Prophylaxe nach Exposition um 75 % im Vergleich zum Placebo reduziert Das Risiko...
March 30, 2022 06:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization

Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis Risk of hospitalization or death in...
March 18, 2022 18:33 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders

WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ: ADGI) today announced that it will hold its 2022 Annual Meeting of Stockholders virtually at 8:30 a.m. Eastern...
February 23, 2022 16:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer

WALTHAM, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
February 22, 2022 07:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

Multiple Initiatives Undertaken for ADG20 Assessment, Including Analysis of Clinical Data at 300mg Dose and Exploring Higher Doses of ADG20 in the Clinic Company Pursuing Portfolio of Antibodies in...
February 18, 2022 19:33 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Announces CEO Succession Plan

WALTHAM, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
January 13, 2022 19:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Divulga Resumo da Atividade Neutralizante do ADG20 Contra Variantes do SARS-CoV-2 e Descreve Iniciativas para Abordar o Omicron

Publicações recentes de vários laboratórios independentes mostram que o ADG20 tem atividade neutralizante com potência comparável a outros anticorpos que retêm atividade contra o Omicron Múltiplos...